DBVT
NASDAQDBV Technologies S.A.
Price$16.05-0.53 (-3.23%)
02:00 PM07:45 PM
News · 26 weeks53-33%
2025-12-142026-06-07
Mix2790d
- Other13(48%)
- SEC Filings12(44%)
- Leadership1(4%)
- Insider1(4%)
Latest news
25 items- PRDBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic condition, including asthma, concomitant food allergy, or atopic dermatitis.DBV will also present the clinical trial design of its recently initiated THRIVE study, which will assess the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of peanuts in infants ages 6 through 12 months with peanut allergy
- PRDBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceChâtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 9:20 AM ET, in Miami, FL. A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event. Ab
- SECSEC Form 8-K filed by DBV Technologies S.A.8-K - DBV Technologies S.A. (0001613780) (Filer)
- SECSEC Form S-8 filed by DBV Technologies S.A.S-8 - DBV Technologies S.A. (0001613780) (Filer)
- PRInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights05/31/2026 296,061,497 Total gross of voting rights: 296,061,497 Total net* of voting rights: 295,906,088 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
- PRDBV Technologies Announces the Results of its 2026 Combined General MeetingChâtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (TRQX:DBVp), a late stage biopharmaceutical company (the "Company"), held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel de Rosen, Chairman of the Board of Directors (the "Board"). The Company's shareholders approved all resolutions submitted by the Board. The resolutions and voting results are posted on the Company's website: 2026 Annual General Meeting | DBV Technologies About DBV TechnologiesDBV Technologies is a late-stage biopharmaceutical company developing tre
- SECSEC Form 8-K filed by DBV Technologies S.A.8-K - DBV Technologies S.A. (0001613780) (Filer)
- PRDBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut AllergyChâtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months with peanut allergyFirst participant screened by Dr. Douglas Mack, Assistant Clinical Professor in the Department of Pediatrics at McMaster University, Ontario DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating
- PRCombined General Meeting of June 3, 2026Châtillon, France, May 13, 2026 Combined General Meeting of June 3, 2026 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company (the "Company"), will hold its Combined General Meeting (the "General Meeting") on June 3, 2026, at 10:00 a.m. CEST (04:00 a.m. EST) at the Company's headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French "Bulletin des Annonces L
- SECAmendment: SEC Form SCHEDULE 13G/A filed by DBV Technologies S.A.SCHEDULE 13G/A - DBV Technologies S.A. (0001613780) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by DBV Technologies S.A.SCHEDULE 13G/A - DBV Technologies S.A. (0001613780) (Subject)
- PRDBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NasdaqChâtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq, which is being held May 19, 2026 in New York, NY. Mr. Tassé's presentation is scheduled for Tuesday, May 19, at 9:00 am ET. A live webcast of the fireside chat can be accessed here and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-o
- SECSEC Form DEF 14A filed by DBV Technologies S.A.DEF 14A - DBV Technologies S.A. (0001613780) (Filer)
- SECSEC Form 8-K filed by DBV Technologies S.A.8-K - DBV Technologies S.A. (0001613780) (Filer)
- SECSEC Form S-8 filed by DBV Technologies S.A.S-8 - DBV Technologies S.A. (0001613780) (Filer)
- SECSEC Form PRE 14A filed by DBV Technologies S.A.PRE 14A - DBV Technologies S.A. (0001613780) (Filer)
- SECDBV Technologies S.A. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - DBV Technologies S.A. (0001613780) (Filer)
- PRDBV Technologies Reports First Quarter 2026 Financial ResultsChâtillon, France, April 30, 2026 DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the second quarter of 2027 following the full exercise of the ABSA Warrants and BS Warrants issued in its March 2025 private placement ("PIPE") financingContinued disciplined execution focused on BLA filing in the first half of this year and commercial preparedness for the U.S. launch of the VIASKIN® Peanut Patch for children aged 4 to 7 years, if approved DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today reported financial results for the first quarter of 2
- SECSEC Form 10-Q filed by DBV Technologies S.A.10-Q - DBV Technologies S.A. (0001613780) (Filer)
- SECAmendment: SEC Form 10-K/A filed by DBV Technologies S.A.10-K/A - DBV Technologies S.A. (0001613780) (Filer)
- INSIDERSEC Form 3 filed by new insider Lee Philina3 - DBV Technologies S.A. (0001613780) (Issuer)
- PRInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights03/31/2026 296,042,447 Total gross of voting rights: 296,042,447 Total net* of voting rights: 295,914,379 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
- SECDBV Technologies S.A. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - DBV Technologies S.A. (0001613780) (Filer)
- SECSEC Form 10-K filed by DBV Technologies S.A.10-K - DBV Technologies S.A. (0001613780) (Filer)
- PRDBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration DocumentChâtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company (the "Company"), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission ("SEC") and its Universal Registration Document (" 2025 URD") with the French market authority, "Autorité des Marchés Financiers" ("AMF"). In compliance with French law, the following information are included in the 2025 URD : The 2025 annual financial report; The Board of Directors' corporate governance report ("rappo
DBVT FAQ
7 questionsWhat does DBV Technologies S.A. do?
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical...Where does DBVT stock trade?
DBV Technologies S.A. (DBVT) is listed on NASDAQ.What sector and industry is DBVT in?
DBV Technologies S.A. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did DBV Technologies S.A. go public?
DBV Technologies S.A. (DBVT) completed its IPO in 2014.What are analysts saying about DBVT?
DBV Technologies S.A. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $4200.00 price target on 2025-12-15.What companies are similar to DBVT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare DBVT side-by-side with any of them on Quantisnow.How can I track DBVT on Quantisnow?
Quantisnow aggregates DBV Technologies S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DBVT to receive live email and push alerts on every new disclosure.